Impact Biomedical IBO
NYSE IBO
$5.32 -0.14 (-2.56%)
At close: Oct 2, 2026 · 4:00 PM EDT

Impact Biomedical (IBO) Cost of Revenue (2025 - 2026)

Updated

Impact Biomedical's Cost of Revenue came in at $1,000 for Q2 2026, unchanged from $1,000 a year earlier.

Analysis

Impact Biomedical (IBO) Cost of Revenue (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 8.05 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.29 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.52 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 1.58 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.09 Bn
10 Impact Biomedical 573.61 Mn 576.81 Mn 2,000.00 1,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1,000.00
Sep 30, 2025 1,000.00
Jun 30, 2025 1,000.00
API Access

Impact Biomedical Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=IBO&period=max&api_key=YOUR_API_KEY